BioAtla Investor Presentation Deck

Phase 2 CAB-AXL (BA3011) NSCLC Interim Analysis BA3011 Monotherapy 1.8 mg/kg Q2W 60 : 50 40 - 30 20 10- 0 -10- -20 -30 -40 -50 -60 bicatla * * confirmed * * Rotow J, Dy GK, Camidge DR. Poster presented at: International Association for the Study of Lung Cancer 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, IL. 60 40 20 0 -20 -40 -60 0 Data Cut Date: 30Jun23 5 10 15 20 Time (Weeks) 25 30 35 40 BioAtla| Overview 34

View entire presentation